Acrivon Therapeutics Inc. has developed a new WEE1/PKMYT1 inhibitor, ACR-2316, to overcome the limitations observed with previous WEE1 and PKMYT1 inhibitors in the treatment of cancer.
Accutar Biotechnology Inc. recently presented preclinical data on AC-4847, a first-in-class PI3Kα-targeting degrader-antibody conjugate (DAC) designed for selective treatment of PI3Kα-driven cancers.
Montse Rosa Therapeutics Inc. has developed a molecular glue degrader named MRT-2359 that selectively degrades the translation termination factor ERF3A.
Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC designed to combine TOP1i and ATR inhibitor (ATRi) mechanisms for enhanced therapeutic efficacy.
Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis.
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.
Advanced gastric cancer continues to pose a significant medical challenge because of the scarcity of effective treatments and the frequent development of resistance to available drugs.
Researchers from Sionna Therapeutics Inc. presented preclinical efficacy data on first-in-class NBD1 stabilizers and their use in combination with complementary modulators to correct cystic fibrosis transmembrane conductance receptor (CFTR) assembly.
In atopic dermatitis (AD), the itch-scratch cycle is tied to skin inflammation exacerbation that accelerates the progression of the disease, thus impacting the patient’s quality of life, where IL-31 is crucial to induce skin itching. Helixon Ltd. has developed a bispecific antibody targeting both IL-31 and OX40L, HXN-1022, for the treatment of AD.
RSS
